Physician profile
Gerard Joseph Meskill
NPI 1295975324
$1,047,210.20
in general payments reported to CMS, 2019-2025
20 companies · $242K in 2025
The $242K reported for 2025 was more than what 99% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $72K · 2021: $108K · 2022: $113K · 2023: $235K · 2024: $184K · 2025: $242K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300K · Consulting Fee: $159K · Honoraria: $126K · Travel and Lodging: $60K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,250 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $299,708.25 |
| Consulting Fee | $158,958.71 |
| Honoraria | $125,569.75 |
| Travel and Lodging | $60,020.22 |
| Food and Beverage | $14,873.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,250.00 |
| Education | $409.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $503,464.02 | 2019-2025 | |
| Harmony Biosciences LLC | $156,367.63 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $148,746.71 | 2022-2025 | Sunosi, Symbravo |
| Avadel Cns Pharmaceuticals, LLC | $129,765.62 | 2023-2025 | Lumryz |
| Lilly USA, LLC | $92,555.70 | 2021-2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $15,672.02 | 2022-2025 | Quviviq, Quviviq |
| Inspire Medical Systems, INC. | $285.75 | 2019-2024 | Inspire |
| Abbvie INC. | $73.32 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $67.39 | 2019-2020 | |
| Amgen INC. | $33.59 | 2022 | |
| Resmed Corp | $27.06 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.07 | 2021 | |
| Zoll Respicardia, INC. | $22.66 | 2024 | Remede System |
| Azurity Pharmaceuticals, INC. | $20.10 | 2025 | Horizant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $18.32 | 2021 | |
| Merck Sharp & Dohme LLC | $17.24 | 2022 | |
| Pfizer INC. | $13.92 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Meskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.